Evolent Health, Inc. (NYSE:EVH) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its holdings in Evolent Health, Inc. (NYSE:EVH - Free Report) by 4.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 912,395 shares of the technology company's stock after selling 45,742 shares during the period. Charles Schwab Investment Management Inc. owned 0.78% of Evolent Health worth $25,803,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EVH. Quarry LP acquired a new position in Evolent Health during the second quarter worth approximately $32,000. Covestor Ltd grew its stake in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock valued at $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC increased its holdings in shares of Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after buying an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Evolent Health in the 2nd quarter worth $61,000. Finally, Quest Partners LLC acquired a new position in Evolent Health in the second quarter valued at $87,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on EVH shares. Royal Bank of Canada restated an "outperform" rating and set a $20.00 price target on shares of Evolent Health in a research note on Tuesday, November 12th. BTIG Research reduced their price target on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating on the stock in a research report on Tuesday. Oppenheimer dropped their price objective on shares of Evolent Health from $34.00 to $28.00 and set an "outperform" rating for the company in a research report on Monday, November 18th. Truist Financial restated a "buy" rating and set a $33.00 target price on shares of Evolent Health in a report on Tuesday, August 27th. Finally, Citigroup lowered their price target on Evolent Health from $33.00 to $21.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Evolent Health has an average rating of "Buy" and an average price target of $26.18.

Evolent Health Stock Down 3.2 %

Shares of EVH stock traded down $0.36 during mid-day trading on Friday, reaching $10.89. 1,206,087 shares of the company were exchanged, compared to its average volume of 1,823,004. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The business's 50 day simple moving average is $20.09 and its 200 day simple moving average is $23.02. The company has a market capitalization of $1.27 billion, a P/E ratio of -12.38 and a beta of 1.45. Evolent Health, Inc. has a fifty-two week low of $10.82 and a fifty-two week high of $35.00.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.